![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
N4 Pharma Plc | LSE:N4P | London | Ordinary Share | GB00BYW8QM32 | ORD 0.4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.075 | 16.67% | 0.525 | 0.50 | 0.55 | 0.525 | 0.45 | 0.45 | 4,522,734 | 16:04:23 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Drug & Proprietary Stores | 2k | -1.27M | -0.0047 | -1.11 | 1.21M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/2/2024 09:13 | Just take some random hidden entity's word for it?. Do you not see all the government, FCA warnings etc ? About how frauds operate on forums | ![]() institutional investments | |
23/2/2024 09:10 | Reminds me of Nobby'sbtx, opti, sbtx, Min...the 25 year history list goes on | ![]() institutional investments | |
23/2/2024 08:57 | It's a fact that the company have said numerous times they are fully funded for their current work and then lo and behold a few months later they do a raise. That's not bashing, that's pointing out that the company has limited resources and zero revenue. There's also a correlation between one of your many aliases popping up and N4 asking for more cash.. funny old world isn't it Farriar | ![]() dplewis1 | |
23/2/2024 08:06 | So it’s just fine for you to ramp on the back of misinformation whereas being sceptical on the basis of facts and my knowledge of the industry is not. There is a whiff of hypocrisy in the air…. | ![]() nobbygnome | |
23/2/2024 07:54 | I counter your points and you sort of try to counter mine. That’s a debate… And until Nuvec or the Nanogenics drug goes into human there is significant risk of some unexpected effect. Mice are inbred with the same genetic makeup to facilitate reproducible experiments whereas humans are ever so slightly outbred….. | ![]() nobbygnome | |
23/2/2024 07:22 | Pharma/biotech don’t take risks. The chances are they will wait for all the pre clinical work to be completed before they even contemplate a deal. Just imagine the poor guy who advocates signing the deal….and then it fails in a tox study. He will have serious egg on his face and his career will be blighted. N4P is desperate for cash and there really is no rush for Pharma to do a deal. Just wait for the N4P price to slump as another fund raise comes along… | ![]() nobbygnome | |
22/2/2024 22:58 | Given the debate about months or years I thought I would just make the point that you do not have to be in clinic to sign licensing deals as this exert demonstrates. ECP 105 is available for licensing as of 09 Aug 2023. hxxps://nanogenics.c | ![]() fydo | |
22/2/2024 21:38 | Nobbles, go tell it to the prisoners Re guild gerbils Haha | ![]() institutional investments | |
22/2/2024 21:31 | At that time I was saying the exact opposite. In the event the PK of the delayed form was dreadful and so it failed before it got to a proper clinical trial… | ![]() nobbygnome | |
22/2/2024 21:16 | Woof woof farriar fido.. very keen to point out it's not insider info! Remember "Sildenafil is a reformulation of a proven drug to make it better. There is no basis for thinking N4's Viagra will be anything but successful".. Nigel's loyal but dimwitted labrador | ![]() dplewis1 | |
22/2/2024 21:09 | Nobbles when you talk about somebody else, are you just giving them your credits ? 😂 | ![]() institutional investments | |
22/2/2024 21:08 | Nibbles your STX advice Nobbygnome - 08 Sep 2022 - Excellent prescription growth and it should accelerate as they get wider insurance coverage and more doctors get used to using the drug. Very impressive ... Did it kick in today again. ? | ![]() institutional investments | |
22/2/2024 21:06 | Farmer Gnome tried to use pesticides like 4D and STX amino acids (what a day today ), to make the tomatoes bloom but they all imploded | ![]() institutional investments | |
22/2/2024 21:01 | This reminds of sbtx and opti with a touch of MIN sprinkle I think those were all produced on the same ramp farm Farmer Gnome | ![]() institutional investments | |
22/2/2024 20:46 | Well 3 years is 36 months but if you say ‘months’ most people would assume less than a year. From the slides there is no chance it will be less than a year hence my assertion you are ramping with misinformation as usual! | ![]() nobbygnome | |
22/2/2024 18:43 | In your original outburst you said ‘within months’ so you must have a figure in your head. Is it 6 or maybe 9 months? The problem here is comments like that which create an expectation which can’t be fulfilled. The reality is it’s likely to be more than 18 months and probably 2 years….if ever of course because it relies on positive results from tox studies etc. | ![]() nobbygnome | |
22/2/2024 18:07 | So to be absolutely clear when do you say a clinical trial will start? | ![]() nobbygnome | |
22/2/2024 16:39 | First of all thanks for the link to the presentation and there’s no doubt that the science around these particles is very interesting and may well be beneficial in various circumstances. I should point out that my job for the last 14 years of my career was creating and presenting this sort of talk so I know precisely the sort of creative writing involved! However my concern has always been the time frames ramped by Fydo and others. Indeed the presentation says the preclinical work required for the Nanogenics particle will take 12-15 months. Assuming positive results from those studies the regulatory requirements to get a trial started will take a number of months maybe longer before a clinical trial will begin. So his assertion that clinical trials will start in months is incorrect and I would say 2 years is the best optimistic guess. This over egging by the rampers is the problem because it creates false expectations for the uninformed! | ![]() nobbygnome |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions